

Special Issue

Resistance in Breast Cancer

Message from the Guest Editors

It is our pleasure to invite you to this Special Issue, entitled *Resistance to Breast Cancer*, which aims to summarize well-known mechanisms of resistance to the various therapies currently available, but also to identify and validate novel and clinically significant biomarkers for the early prediction of response/resistance to therapy and the prognosis of breast cancer. In this Special Issue, original research articles and cutting-edge reviews are welcome. Research areas may include (but are not limited to) the following:

- Biomarkers of endocrine resistance;

- CDK 4/6 inhibitor resistance;
- Breast cancer heterogeneity;
- Mechanisms of resistance to anti-Her2 therapies;
- Mechanisms of resistance to ADCs;
- Mechanisms of immune evasion in triple-negative breast cancer;
- Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer;
- Mechanisms of resistance to PARP inhibitors.

Guest Editors

Dr. Sonia Pernas

1. Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

2. Breast Cancer Group, Institut d'Investigació Biomedica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

Dr. Romualdo Barroso

Oncology Center, Hospital Sírio-Libanês Brasília, Brasília, Brazil

Deadline for manuscript submissions

closed (15 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/114589

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)